RINGPU(SZ:300119) Xin Lang Zheng Quan·2025-11-03 06:15Core Viewpoint - The stock price of Reap Bio fell by 2.09% on November 3, with a trading volume of 140 million yuan and a market capitalization of 9.806 billion yuan [1] Company Overview - Reap Bio, established on August 2, 2001, and listed on September 17, 2010, is located in the Tianjin Free Trade Zone. The company specializes in the research, production, and sales of veterinary biological products, chemical drugs, biological agents, traditional veterinary medicine, natural plant medicines, premixed feeds, feed additives, and veterinary raw materials [2] - The main business revenue composition is 77.95% from animal protection and 22.05% from the pet supply chain [2] - As of October 20, 2023, the number of shareholders is 25,000, with an average of 13,398 circulating shares per person [2] Financial Performance - For the period from January to September 2025, Reap Bio achieved a revenue of 2.544 billion yuan, representing a year-on-year growth of 45.66%. The net profit attributable to the parent company was 362 million yuan, with a year-on-year increase of 48.04% [2] - Since its A-share listing, Reap Bio has distributed a total of 1.371 billion yuan in dividends, with 462 million yuan distributed over the past three years [3] Shareholding Structure - As of September 30, 2025, the sixth largest circulating shareholder is the Guotai Zhongzheng Livestock Breeding ETF, holding 6.3383 million shares, an increase of 2.3571 million shares from the previous period. The Hong Kong Central Clearing Limited is the tenth largest shareholder, holding 3.6017 million shares, a decrease of 2.9711 million shares from the previous period [3]